{
    "nct_id": "NCT05753306",
    "official_title": "A Phase II Study of Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Gastric Cancer and Limited Peritoneal Metastasis: ROBO-CHIP Trial",
    "inclusion_criteria": "* Restricted to 18 to 80 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n* Histologic confirmation of gastric adenocarcinoma including all subtypes and Siewert type II/III gastroesophageal (GE) junction adenocarcinomas\n* Absolute neutrophil count >= 1,500 / uL\n* Platelets >= 50,000 / Ul\n* Serum creatinine <= 1.5 mg / dL\n* Adequate nutritional status (Albumin >= 3.5)\n* Metastasis confined to the peritoneum:\n\n  * Positive peritoneal cytology\n  * Peritoneal metastasis on diagnostic laparoscopy\n  * Peritoneal metastasis on imaging\n* Response to systemic chemotherapy defined as at least one of the following:\n\n  * Reduction (>= 30%) in standardized uptake value (SUV) max [Response Evaluation Criteria in Solid Tumors (RECIST) criteria]\n  * Reduction in size of primary tumor, regional lymph node or peritoneal metastasis on imaging (>= 20% decrease in the longest diameter of target lesion) RECIST criteria\n  * Reduction ( >= 30%) in Peritoneal Carcinomatosis Index (PCI) or conversion of peritoneal cytology\n  * Reduction ( >= 30%) in serum tumor markers CEA or CA 19-9\n* Peritoneal Carcinomatosis Index (PCI) =< 7 and surgeon deems high likelihood for a complete cytoreduction\n* Body Mass Index (BMI) =< 35 kg/m^2\n* Must enroll in Institutional Review Board (IRB) 14-009873 (NCT02530983)\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Distant metastatic disease not limited to peritoneum, such as solid organ metastases (liver, lung, bone, distant lymph node, etc)\n* Malignant ascites at time of study enrollment\n* Comorbidities that would preclude protocol therapy\n* Subjects deemed unable to comply with study and/or follow-up procedures\n* Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity",
    "miscellaneous_criteria": ""
}